These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22404965)

  • 1. A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.
    von Euler H; Rivera P; Nyman H; Häggström J; Borgå O
    Vet Comp Oncol; 2013 Dec; 11(4):243-55. PubMed ID: 22404965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas.
    Rivera P; Akerlund-Denneberg N; Bergvall K; Kessler M; Rowe A; Willmann M; Persson G; Kastengren Fröberg G; Westberg S; von Euler H
    J Small Anim Pract; 2013 Jan; 54(1):20-7. PubMed ID: 23190121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs.
    Vail DM; von Euler H; Rusk AW; Barber L; Clifford C; Elmslie R; Fulton L; Hirschberger J; Klein M; London C; Martano M; McNiel EA; Morris JS; Northrup N; Phillips B; Polton G; Post G; Rosenberg M; Ruslander D; Sahora A; Siegel S; Thamm D; Westberg S; Winter J; Khanna C
    J Vet Intern Med; 2012; 26(3):598-607. PubMed ID: 22390318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of the chemotherapy agent water-soluble micellar paclitaxel (Paccal Vet) on canine hemangiosarcoma cell lines.
    Reckelhoff CR; Lejeune A; Thompson PM; Shiomitsu K
    Vet Comp Oncol; 2019 Mar; 17(1):32-41. PubMed ID: 30267450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of intravenous and subcutaneous administration of a novel, excipient-free, nanoparticulate formulation of paclitaxel in dogs with spontaneously occurring neoplasia.
    Selting KA; Bechtel SM; Espinosa J; Henry CJ; Tate D; Bryan JN; Rajewski L; Flesner BK; Decedue C; Baltezor M
    Vet Comp Oncol; 2018 Dec; 16(4):650-657. PubMed ID: 30182530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
    J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors.
    Poirier VJ; Hershey AE; Burgess KE; Phillips B; Turek MM; Forrest LJ; Beaver L; Vail DM
    J Vet Intern Med; 2004; 18(2):219-22. PubMed ID: 15058774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs.
    Axiak SM; Selting KA; Decedue CJ; Henry CJ; Tate D; Howell J; Bilof KJ; Kim DY
    Int J Nanomedicine; 2011; 6():2205-12. PubMed ID: 22072863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
    J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs.
    Khanna C; Rosenberg M; Vail DM
    J Vet Intern Med; 2015; 29(4):1006-12. PubMed ID: 26179168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
    Mita M; Mita A; Sarantopoulos J; Takimoto CH; Rowinsky EK; Romero O; Angiuli P; Allievi C; Eisenfeld A; Verschraegen CF
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):287-95. PubMed ID: 19034451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
    Chang AY; Boros L; Asbury R; Hui L; Rubins J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-69-S17-71. PubMed ID: 9374098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of hydrophilic Paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models.
    Zou Y; Fu H; Ghosh S; Farquhar D; Klostergaard J
    Clin Cancer Res; 2004 Nov; 10(21):7382-91. PubMed ID: 15534115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
    Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
    Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
    Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
    Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.